IOL Chemicals and Pharmaceuticals Limited

rs,

stries like pharmaceuticals, ink industry, flexible packaging, adhesives, surface coatings, flavours, paints & lamination and essences etc. Captive co-generation unit with capacity of 17 MW to meet pow

17 MW

tings, flavours, paints & lamination and essences etc. Captive co-generation unit with capacity of 17 MW to meet power and steam requirements To be amongst the most admired companies in APIs, Intermedia

30%

tion Iso Butyl Benzene (IBB) commercialised with 12 company worldwide being in India with ~30% Global share products in pipeline backward integrated with ~35% Global share Debt free company

35%

rldwide being in India with ~30% Global share products in pipeline backward integrated with ~35% Global share Debt free company, Spread over a sprawling Zero Discharge Effluent Customer base

rs. 5

umar Rana (Director – Works) after quality assurance, quality control & corporate regulatory affairs. 5 Experienced Independent Directors • Mr. Rajender has very distinguished career of four • Mr. Harpa

4MW

ement of Acetic Anhydride Plant 1999 Unit-01 Ibuprofen (Dedicated) Co-Generation Plant – 4MW 2000 Commencement of Ibuprofen Unit-1 2007 Listing on NSE Co-Generation Plant – 13MW 2010

13MW

lant – 4MW 2000 Commencement of Ibuprofen Unit-1 2007 Listing on NSE Co-Generation Plant – 13MW 2010 2009 Commencement of IBB, MCA and Acetyl Chloride Plants *Unit-10 was commercialized i

20%

tiles Ink Paints Pesticides 12 Product wise Revenue Segmentation – Quarterly Q4FY22 572 112 20% 183 32% 277 48% Q3FY22 555 96 17% 160 29% 299 54% Q4FY21 460 50 11% 168 37% 242 53% Ch

32%

k Paints Pesticides 12 Product wise Revenue Segmentation – Quarterly Q4FY22 572 112 20% 183 32% 277 48% Q3FY22 555 96 17% 160 29% 299 54% Q4FY21 460 50 11% 168 37% 242 53% Chemicals

48%

Pesticides 12 Product wise Revenue Segmentation – Quarterly Q4FY22 572 112 20% 183 32% 277 48% Q3FY22 555 96 17% 160 29% 299 54% Q4FY21 460 50 11% 168 37% 242 53% Chemicals Ibuprofen

17%

duct wise Revenue Segmentation – Quarterly Q4FY22 572 112 20% 183 32% 277 48% Q3FY22 555 96 17% 160 29% 299 54% Q4FY21 460 50 11% 168 37% 242 53% Chemicals Ibuprofen Other API’s All fi

29%

Revenue Segmentation – Quarterly Q4FY22 572 112 20% 183 32% 277 48% Q3FY22 555 96 17% 160 29% 299 54% Q4FY21 460 50 11% 168 37% 242 53% Chemicals Ibuprofen Other API’s All figures in

For further details

1